Kulis_Timothy

Timothy J. Kulis

Kulis_Timothy

Timothy J. Kulis

Senior Associate

Timothy (Tim) Kulis represents public and private companies at all stages of growth in corporate and securities law matters. He represents companies in mergers and acquisitions, public offerings and venture capital financings. In addition, he advises public company clients on ongoing corporate legal matters, including federal securities reporting requirements. Mr. Kulis represents clients in a range of industries, including technology, life sciences and defense.

Mr. Kulis was previously a summer associate in WilmerHale's Boston office, and at another Boston law firm. Prior to law school, he worked for US-based multinational e-commerce company Wayfair and served as a legislative aide intern in the office of Massachusetts Senator Robert L. Hedlund.

Experience

  • Capital Markets

    • Pandion Therapeutics in its $152.9 million initial public offering of common stock
    • Dynatrace’s $655 million initial public offering of common stock and follow-on public offerings of common stock raising a total of $1.6 billion (underwriters’ counsel)
    • Karyopharm Therapeutics in its $150 million offering of convertible senior notes
    • Translate Bio in its $121.6 million initial public offering of common stock, $47.5 million private placement and $90 million follow-on public offering of common stock
    • EverQuote in its $84.4 million initial public offering of Class A common stock
    • Tetraphase Pharmaceuticals in its $65 million follow-on public offering of common stock, $8 million registered direct offering and $17.5 million registered direct offering and concurrent private placement
    • Blue Apron in its $300 million initial public offering of Class A common stock and $37 million follow-on public offering of Class A common stock
    • Aileron Therapeutics in its $56.3 million initial public offering of common stock
    • Catabasis Pharmaceuticals in its $11.5 million follow-on public offering of common stock
    • MacroGenics’ $150 million follow-on public offering of common stock (underwriters’ counsel)
    • CoNCERT Pharmaceuticals in its $50 million follow-on public offering of common stock
    • Endurance International Group in its $262 million follow-on public offering of common stock
  • Venture Capital Transactions

    • Pandion Therapeutics in its $80 million Series B financing and $6 million SAFE financing
    • Notch Therapeutics in its $5 million Series Seed financing
    • Embark Veterinary in its $12.9 million Series A financing
    • Translate Bio in its Series C financing
    • Blue Apron in its $64.6 million convertible promissory note financing
    • Aileron Therapeutics in its Series F financing
    • Dataxu in its $20 million late-stage financing
    • Blue Apron in its $135 million Series D financing
  • Mergers and Acquisitions

    • Dataxu in its acquisition by Roku for $150 million
    • CIRCOR International in its acquisition of Colfax’s fluid handling business for $855 million
    • American Science and Engineering in its acquisition by OSI Systems for $269 million
    • PAREXEL International in its acquisition of Health Advances
    • Thermo Fisher Scientific in its acquisition of Alfa Aesar research chemicals business of Johnson Matthey for $405 million

Insights & News

Credentials

  • Education

    • JD, Boston College Law School, 2014

      cum laude Senior Editor, Boston College Law Review
    • BA, Political Science, Boston College, 2009

      summa cum laude
  • Admissions

    • Massachusetts

Credentials